ESSENTIAL FUNCTIONS AND RESPONSIBILITIES:
- Set and execute the strategic vision for clinical development in autoimmune diseases, ensuring alignment with corporate goals and maximizing portfolio value.
- Lead cross-functional teams in the design and implementation of clinical development strategies, focusing on innovation, differentiation, and speed to market.
- Oversee clinical program execution at a strategic level, delegating operational and hands-on responsibilities to clinical teams and direct reports.
- Maintain ultimate accountability for medical monitoring, ensuring patient safety and clinical integrity, but delegate day-to-day monitoring activities to appropriate team members.
- Provide expert guidance and strategic input on clinical trial design, regulatory strategy, and data interpretation.
- Serve as the primary medical and scientific spokesperson for the immunology franchise, internally and externally.
- Cultivate relationships with key opinion leaders, investigators, and external partners to advance Janux’s immunology pipeline.
- Drive organizational growth, talent development, and succession planning within the clinical development function.
- Other duties as deemed essential
EDUCATION, EXPERIENCE, KNOWLEDGE, SKILLS AND ABILITIES
- MD or DO with subspecialty in immunology, autoimmune diseases, or related fields.
- Demonstrated success as a senior clinical leader (e.g., therapeutic area head, franchise lead) in large pharma or biotech, with broad immunology experience.
- Proven track record of strategic leadership in clinical development, portfolio management, and cross-functional team building.
- Innovative, entrepreneurial mindset; experience driving change and building new capabilities.
- Deep understanding of early drug development, clinical trial processes, and regulatory requirements in immunology/inflammation.
- Exceptional communication, influence, and stakeholder management skills.
- Strong ability to critically evaluate data, literature, and presentations.
- High level of communication skills is expected.